Furthermore, robust tumor growth persisted in 5 of the 8 mice that we continued to monitor after anti-IFNAR1 treatment was halted on day 12, and only moderate regression was observed in the 3 other mice, despite ongoing CPA treatment. Here, IFNAR1 is linked to neoplasm.